4.5 Review

Diagnostic accuracy of TB-LAMP for pulmonary tuberculosis: a systematic review and meta-analysis

Journal

BMC INFECTIOUS DISEASES
Volume 19, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s12879-019-3881-y

Keywords

Tuberculosis; Diagnostic testing; Molecular assay; Point of care

Funding

  1. Global TB Programme of the World Health Organization

Ask authors/readers for more resources

BackgroundThe need for a rapid, molecular test to diagnose tuberculosis (TB) has prompted exploration of TB-LAMP (Eiken; Tokyo, Japan) for use in resource-limited settings. We conducted a systematic review to assess the accuracy of TB-LAMP as a diagnostic test for pulmonary TB.MethodsWe analyzed individual-level data for eligible patients from all studies of TB-LAMP conducted between Jan 2012 and October 2015 to compare the diagnostic accuracy of TB-LAMP with that of smear microscopy and Xpert MTB/RIF (R) using 3 reference standards of varying stringency. Pooled sensitivity and specificity and pooled differences in sensitivity and specificity were estimated using random effects meta-analysis. Study quality was evaluated using QUADAS-2.ResultsFour thousand seven hundred sixty individuals across 13 studies met eligibility criteria. Methodological quality was judged to be low for all studies. TB-LAMP had higher sensitivity than sputum smear microscopy (pooled sensitivity difference+132, 95% CI 45-219%) and similar sensitivity to Xpert MTB/RIF (pooled sensitivity difference-25, 95% CI -80 to +29) using the most stringent reference standard available. Specificity of TB-LAMP was similar to that of sputum smear microscopy (pooled specificity difference-18, 95% CI -38 to +02) and Xpert MTB/RIF (pooled specificity difference 05, 95% CI -09 to +18).ConclusionsFrom the perspective of diagnostic accuracy, TB-LAMP may be considered as an alternative test for sputum smear microscopy. Additional factors such as cost, feasibility, and acceptability in settings that continue to rely on sputum smear microscopy should be considered when deciding to adopt this technology. Xpert MTB/RIF should continue to be preferred in settings where resource and infrastructure requirements are adequate and where HIV co-infection or drug-resistance is of concern.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available